Alpha-9 Theranostics Inc., a clinical-stage firm focusing on radiopharmaceuticals for cancer treatment, has successfully secured $75 million in an oversubscribed Series B financing. Nextech Invest spearheaded the round, with contributions from Frazier Life Sciences, Samsara BioCapital, Quark Venture, Longitude Capital, and BVF Partners. Alpha-9 is designing bespoke radiopharmaceuticals for solid and hematologic malignancies. These radiopharmaceuticals aim to precisely target tumor sites, reducing off-target impacts. The newly-acquired funds will propel the company's five programs into clinical trials in the upcoming two years and boost its preliminary projects. David Hirsch, Alpha-9's CEO, expressed gratitude for the support from prominent investors, which will further their advancements in cancer treatments. The company's unique method in radiotherapeutic design, driven by a collection of technologies and chemistries, has vast potential in addressing multiple oncology targets. By leveraging its founders' profound knowledge in modifying peptides and small molecules, Alpha-9 enhances every aspect of its radiopharmaceuticals, from binders to radioisotopes. This method is cost-efficient and swift, ensuring thorough vetting of compounds before extensive clinical trials. Melissa McCracken from Nextech Invest praised the evolution and potential of the radiopharmaceutical domain, emphasizing Alpha-9's significant progress. The Series B funding will also aid Alpha-9 in expanding its team, establishing research facilities in Vancouver, BC, and investing in radioisotope supplies. Alpha-9, established in 2019, is based in both Boston and Vancouver and was founded by experts from BC Cancer and the University of British Columbia. Several top-tier members from the investing firms will join Alpha-9's Board of Directors.